Skip to content

Organon OGN Share-Based Payment - Unrecognized Cost of Nonvested Awards

Share-Based Payment - Unrecognized Cost of Nonvested Awards at other companies

Balchem logo
BalchemBCPC
$35.8M+13.9%
Bicara Therapeutics logo
Bicara TherapeuticsBCAX
$72.5M+113%
Hope Bancorp logo
Hope BancorpHOPE
$0
Hercules Capital logo
Hercules CapitalHTGC
$34.5M+14.6%
First Busey Corporation logo
First Busey CorporationBUSE
$9.87M-67.3%
Calix logo
CalixCALX
$61.6M-42.3%

Other financials

Income statement

See full
Revenue$1.5B-3.5%
Gross profit$783.0M-6.9%
Net income$146.0M+67.8%
EPS (diluted)$0.55+66.7%

Balance sheet

See full
Cash & equivalents$1.1B+104%
Total debt$8.6B-4.3%
Total equity$903.0M+66.6%
Total assets$13.0B-1.2%

Cash flow

See full
Operating cash flow$225.0M+200%
CapEx$37.0M+15.6%
Free cash flow$188.0M+337%

Valuation

See full
Market cap$3.53B-59.4%

Profitability

See full
Gross margin52.8%-4.4pp
Net margin8%-12.3pp
FCF margin11.1%-1.3pp

Returns & leverage

See full
Return on equity71.6%
Debt / equity9.5×-7.0×
Current ratio+0.3×

Where this comes from

Reported directly by Organon in its filing.

Tagged under the XBRL concept us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized.

The official record: Organon’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Organon's share-based payment - unrecognized cost of nonvested awards.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Organon's share-based payment - unrecognized cost of nonvested awards?
Organon (OGN) reported share-based payment - unrecognized cost of nonvested awards of $179M in Q1 2026.
How has Organon's share-based payment - unrecognized cost of nonvested awards changed year-over-year?
Organon's share-based payment - unrecognized cost of nonvested awards decreased by 19.0% year-over-year, from $221M to $179M.
What does share-based payment - unrecognized cost of nonvested awards mean?
This represents the total compensation expense for equity-based awards that has been granted but not yet recognized in the income statement because the vesting conditions have not been met. It serves as a forward-looking indicator of future non-cash compensation expenses. Investors use this to forecast the impact of stock-based compensation on future earnings.